GO
| HSI1 | 24,642.51 | +132.42 | 177.48B |
| HSCEI1 | 8,216.84 | +51.06 | 51.28B |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP (01177.HK) Forms Strategic Biosimilar Partnership with STADA with Milestone Payments Up to HKD473 Million
2026-09-28 16:59:48 SBP GROUP (01177.HK) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group has entered into a strategic cooperation agreement with STADA Arzneimittel AG on biosimilars, with both parties aiming to improve patient accessibility to biosimilars across multiple global regions. Under the agreement terms, Chia Tai Tianqing will receive an upfront payment and will be eligible for potential development, regulatory and sales milestone payments totaling up to EUR53 million, equivalent to approximately HKD473 million. Meanwhile, Chia Tai Tianqing will also be entitled to a double-digit profit share generated from the pembrolizumab biosimilar candidate within the licensed territories. Chia Tai Tianqing will grant STADA an exclusive license to commercialize the pembrolizumab biosimilar candidate (TQB3570, an anti-PD-1 monoclonal antibody) in the European Union, Switzerland, the United Kingdom and the Commonwealth of Independent States. In addition, STADA has options to add up to three other biosimilar molecules covering oncology and immunology fields. Chia Tai Tianqing will lead the research and development, manufacturing and commercial supply of the biosimilar candidates within the licensed territories, while STADA will hold the marketing authorizations and exclusive sales and marketing rights for the biosimilars in those territories. STADA also holds options for the United States and Gulf Cooperation Council (GCC) member states. SBP GROUP stated that since the beginning of the year it has completed multiple out-licensing transactions, with total upfront and near-term milestone payments reaching USD355 million and potential total deal value amounting to USD3.4 billion. (gc/ad)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |